Allott Kelly, Yassin Walid, Alameda Luis, Billah Tashrif, Borders Owen, Buccilli Kate, Carrión Ricardo E, Castillo-Passi Rolando I, Cho Kang Ik K, Chin Kota, Coleman Michael J, Colton Beau-Luke, Corral Sebastián, Dwyer Dominic, Gundersen Kristina Ballestad, Gur Ruben C, Hoftman Gil D, Jacobs Grace R, Kelly Sinead, Lewandowski Kathryn E, Marcy Patricia J, Matneja Priya, McLaughlin Danielle, Nunez Angela R, Parsa Setari, Penzel Nora, Ray Susan, Reinen Jenna M, Ruparel Kosha, Sand Michael S, Santorelli Gennarina, Seitz-Holland Johanna, Spark Jessica, Tamayo Zailyn, Thompson Andrew, Tod Sophie, Wannan Cassandra M J, Wickham Alana, Wood Stephen J, Zoupou Eirini, Addington Jean, Anticevic Alan, Arango Celso, Breitborde Nicholas J K, Broome Matthew R, Cadenhead Kristin S, Calkins Monica E, Chen Eric Yu Hai, Choi Jimmy, Conus Philippe, Corcoran Cheryl M, Cornblatt Barbara A, Ellman Lauren M, Fusar-Poli Paolo, Gaspar Pablo A, Gerber Carla, Glenthøj Louise Birkedal, Horton Leslie E, Hui Christy Lai Ming, Kambeitz Joseph, Kambeitz-Ilankovic Lana, Keshavan Matcheri, Kim Sung-Wan, Koutsouleris Nikolaos, Kwon Jun Soo, Langbein Kerstin, Mamah Daniel, Diaz-Caneja Covadonga M, Mathalon Daniel H, Mittal Vijay A, Nordentoft Merete, Pearlson Godfrey D, Perkins Diana O, Perez Jesus, Powers Albert R, Rogers Jack, Sabb Fred W, Schiffman Jason, Shah Jai L, Silverstein Steven M, Smesny Stefan, Strauss Gregory P, Thompson Judy L, Upthegrove Rachel, Verma Swapna K, Wang Jijun, Wolf Daniel H, Pasternak Ofer, Bouix Sylvain, McGorry Patrick D, Kane John M, Kahn Rene S, Bearden Carrie E, Shenton Martha E, Woods Scott W, Nelson Barnaby, Stone William S
Orygen, Parkville, VIC, Australia.
Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1.
Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.
与健康同龄人相比，临床高危（CHR）精神病个体的认知障碍发生率更高，并且它为向精神病转变的多变量预测模型贡献了独特的方差。这种障碍被认为是精神分裂症的核心生物标志物。因此，认知是精神分裂症加速药物合作计划（AMP SCZ计划）中测量的关键领域。本文的目的是描述AMP SCZ在两个数据收集网络中使用的认知测试组合的基本原理、过程、注意事项和最终协调。该测试组合包括一般智力和特定认知领域的测试。我们在基线时估计病前智力，并在基线和2年时测量当前智力。宾夕法尼亚计算机化神经认知测试组合（PennCNB）中的八项测试，用于测量言语学习和记忆、感觉运动能力、注意力、情绪识别、工作记忆、处理速度、言语记忆、视觉记忆和运动速度，在基线时以及2年中的四个随访时间点重复进行测试。
